

PreOmics Launches New Plasma Proteomics Solution P2-iST and Announces the Formation of Bignosys Group

- **P2-iST Plasma Launch:** The new nanoparticle-based plasma proteomics workflow combines Bignosys' P2 Plasma Enrichment with PreOmics' iST technology, achieving identification of nearly 6,000 plasma proteins with >90% data completeness, exceptional precision, and scalability up to 192 samples processed per day.
- **Formation of Bignosys Group:** PreOmics joins forces with Bignosys and biocrates under Bruker to form the Bignosys Group—an integrated multiomics leader delivering comprehensive proteomics, metabolomics, and lipidomics solutions through vendor-neutral, scalable technologies.

TORONTO, Canada, November 10th, 2025 – PreOmics GmbH, now part of Bignosys Group, a global leader in mass spectrometry-based multiomics solutions, today announced the launch of the P2-iST Plasma solution at the HUPO World Conference, taking place November 9–13 in Toronto, Canada.

Formation of the Bignosys Group

PreOmics has become part of the newly established Bignosys Group, an affiliate of Bruker. The Bignosys Group delivers high-performance, robust solutions across proteomics, metabolomics, and lipidomics, driving innovation at the forefront of multiomics. Building on the combined strengths of PreOmics, Bignosys, and biocrates, the Group develops and commercializes industry-leading consumables, software, instruments, and CRO services to make advanced mass spectrometry workflows seamless, scalable, and accessible to every laboratory. Maintaining a vendor-neutral position, Bignosys Group ensures broad compatibility of its solutions with all major mass spectrometry platforms. Designed for agility, the Group's solutions can operate independently or as part of a unified ecosystem, supported by flexible business models and a strong commitment to partnership.

Launch of P2-iST Plasma Solution

The Bignosys Group has launched the P2-iST Plasma solution, a next-generation technology that unites the proven performance of Bignosys' P2 Plasma Enrichment with the robustness of PreOmics' iST technology. This innovative nanoparticle-based plasma workflow delivers unprecedented proteome depth, identifying nearly 6,000 proteins with >90% data completeness across a pilot study of 12 cancer and healthy plasma samples. Benchmarking studies further demonstrate its exceptional quantitative precision, setting a new standard for plasma proteomics performance.

Built for scalability and efficiency, the P2-iST Plasma solution allows processing of up to 192 samples per day using standard automation platforms, providing a flexible, cost-effective, and highly reliable solution for a wide range of research applications.

Designed for seamless integration into any laboratory environment, the P2-iST Plasma solution is available through flexible business models, ranging from research-use kits to

dedicated CRO services. The technology is currently offered under Early Access, including comprehensive method transfer and implementation support for selected expert laboratories.

Biognosys Group at HUPO 2025

At HUPO 2025, Biognosys Group will present groundbreaking innovations in proteomics, featuring three oral presentations focused on biomarker discovery using P2 Enrichment Technology in plasma and cerebrospinal fluid, advancing research in cancer and neurodegenerative diseases.

During a breakfast seminar entitled “Expert Solutions for Real-World Research Challenges,” industry and academic experts will showcase the latest advances in mass spectrometry-based plasma proteomics and immunopectidomics, highlighting how Biognosys Group’s technologies are enabling deeper biological insights and translational discoveries.

In addition, Biognosys Group will present 16 scientific posters spanning its proteomics consumables, software, and CRO solutions, demonstrating breakthroughs in immunopectidomics, automation for large-scale degrader screening, and its Digital Proteome – a multi-species, multi-tissue proteome expression atlas. Further highlights include advancements in host cell protein quantification and FFPE sample profiling using PreOmics’ BeatBox®.

Join Biognosys Group at Booths #703 and #803 at HUPO 2025 to explore how its cutting-edge proteomics solutions are driving the new frontier of biomarker discovery and translational research.

For more information, contact:

Dr. Garwin Pichler, Founder & Managing Director PreOmics GmbH

Email: info@preomics.com

Website: www.preomics.com

Address: Am Klopferspitz 19 | 82152 Planegg/Martinsried | Germany